• 1
    Schmid C,Labopin M,Nagler A, et al. DLI in the treatment of first hematological relapse after allogeneic Stem cell transplantation in adults with AML: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia WP. J Clin Oncol 2007; 25: 49384945.
  • 2
    Hallemeier CL,Girgis MD,Blum WG, et al. Long-term remissions in patients with MDS and secondary AML undergoing allogeneic trasplantation following a reduced intensity conditioning regimen of 550 cGy TBI and Cyclophosphamide. BBMT 2006; 12: 749757.
  • 3
    Vicente D,Lamparelli T,Gualandi F, et al. Improved outcome in young adults with de novo AML in first remission, undergoing an allogeneic bone marrow transplantation. BMT 2007; 40: 349354.
  • 4
    Graef T,Vaupel M,Fenk R, et al. Prognostic factors for patients with AML or high risk MDS undergoing mieloablative or non-myeloablative allogeneic blood SCT. Hematol Oncol 2007; 20: 170177.
  • 5
    Sorror M,Sandmaier BM,Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with AML or MDS receiving allogeneic HSCT. J Clin Oncol 2007; 20: 42464254.
  • 6
    Nakamura R,Rodriguez R,Palmer J, et al. RIC for allogeneic HSCT with fludarabine and melphalan is associated with durable disease control in MDS. BMT 2007; 40: 843850.
  • 7
    Pollyea DA,Artz AS,Stock W, et al. Outcome of patients with AML and MDS who relapse or progress after EIC allogeneic hematopoietic cell transplatation. BMT 2007; 40: 10271032.
  • 8
    Pérez-Simón JA,Caballero D,Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 14231431.
  • 9
    Collins RH,Shpilberg O,Drobyski WR, et al. Donor leukocyte infusions in 140 patients relapsed with malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433444.
  • 10
    Spinelli O,Peruta B,Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007; 92: 612618.
  • 11
    Uzumel M,Mattsson J,Jaksch M, et al. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001; 98: 19821984.
  • 12
    Radich J,Gehly G,Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 26022609.
  • 13
    Radich J,Gehly G,Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 1995; 85: 26322638.
  • 14
    Sramkova L,Muzikova K,Fronkova E, et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 93100.
  • 15
    Sánchez-García J,Senano J,Gomez P, et al. La Calidad de la remisión cuantificada por CMF multiparamática es factor pronóstico independiente en pacientes afectos de LAL sometidos a trasplante alogénico de precursores hematopoyéticos. Congreso nacional de la Asociación Española de Hematología y Hemoterapia, Pamplona, Spain, 2007, plenary session SP-05.
  • 16
    San Miguel JF,Martínez A,Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 24652470.
  • 17
    San Miguel JF,Almeida J,Ocqueteau M. Immunophenotyping and DNA ploidy analysis for detection of minimal residual disease in MM. Cancer Res Therapy Control 1998; 6: 299302.
  • 18
    Ciudad J,San Miguel JF,López-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 37743781.
  • 19
    San Miguel JF,Ciudad J,Vidriales MB, et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol 1999; 32: 175185.
  • 20
    Vidriales MB,Pérez JJ,López-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003; 101: 46954700.
  • 21
    San Miguel JF,Vidriales MB,Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 17461751.